News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Lexicon Genetics Incorporated (LEXG) Initiates Phase 2 Clinical Trial of LX2931 in Patients With Rheumatoid Arthritis



8/4/2009 7:58:07 AM

THE WOODLANDS, Texas, Aug. 4 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. , a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that it has initiated a Phase 2 clinical trial of LX2931 in patients with rheumatoid arthritis. LX2931 is an orally-delivered, small molecule drug candidate that has recently completed Phase 1 testing in normal volunteers. Lexicon also successfully completed a drug-drug interaction (DDI) study of LX2931 with methotrexate in patients with rheumatoid arthritis, with no clinically significant drug-drug interactions observed.

LX2931 inhibits sphingosine-1-phosphate (S1P) lyase, an enzyme identified by Lexicon scientists as a promising new target on a pathway associated with regulation of the human immune system. Lexicon has previously shown that genetically "knocking out" or "knocking down" S1P lyase in mice substantially decreased the inflammatory response in multiple models of arthritis, inflammation and transplantation.

In addition to LX2931, Lexicon has two other drug candidates progressing in Phase 2 clinical trials, LX1031 for irritable bowel syndrome and LX1032 for carcinoid syndrome. Furthermore, LX4211 for diabetes has recently completed dosing in a Phase 1 clinical trial. For more information about Lexicon's clinical development programs, please visit www.lexpharma.com.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease. Lexicon currently has five drug candidates in development for autoimmune disease, carcinoid syndrome, diabetes, glaucoma and irritable bowel syndrome, all of which were discovered by the company's research team. The company has used its proprietary gene knockout technology to identify more than 100 promising drug targets. Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs. For additional information about Lexicon and its programs, please visit www.lexpharma.com.

SOURCE Lexicon Pharmaceuticals, Inc.

CONTACT: Jason Ray, Manager, Corporate Communications and Investor
Relations of Lexicon Pharmaceuticals, Inc., +1-281-863-3225,
jray@lexpharma.com

Web site: http://www.lexpharma.com/


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES